初晓丽

沈阳市第四人民医院肿瘤血液科，辽宁沈阳110032

吉西他滨联合方案在治疗复发难治性非霍奇金淋巴瘤中的疗效观察

初晓丽

沈阳市第四人民医院肿瘤血液科，辽宁沈阳110032

目的探讨吉西他滨联合方案治疗复发难治性非霍奇金淋巴瘤的临床疗效。方法选择2011年6月～2016年1月期间我院收治的106例复发难治性非霍奇金淋巴瘤患者，将所有患者按照治疗方法分为观察组和对照组，各53例。观察组用吉西他滨联合方案治疗（吉西他滨、奥沙利铂、地塞米松），对照组用CHOP化疗方案进行治疗，一个周期为21 d，疗效的评定于两个周期后进行。比较两组患者的临床疗效及毒副作用发生情况。结果观察组RR高于对照组，差异有统计学意义（P＜0.05）。观察组白细胞减少、血小板减少、发热、消化道反应及其他不良反应发生率低于对照组，差异有统计学意义（P＜0.05）；观察组贫血、周围神经毒性发生率与对照组比较，差异无统计学意义（P＞0.05）。结论复发难治性非霍奇金淋巴瘤采用吉西他滨联合方案治疗有一定疗效，毒副反应较轻微，患者可耐受。

淋巴瘤曰复发难治性曰吉西他滨曰奥沙利铂曰地塞米松

［Abstract］Objective To investigate the clinical effect of joint program of gemcitabine in the treatment of relapsed or refractory non-Hodgkin's lymphoma.Methods 106 cases of CPC relapsed or refractory non-Hodgkin's lymphoma patients were selected from June 2011 to January 2016 in our hospital，all the patients were divided into observation group（n=53）and control group（n=53）according to the treatment methods.Patients in observation group were treated with gemcitabine in combination with chemotherapy（gemcitabine，oxaliplatin，dexamethasone），and the control group was treated with CHOP regimen therapy，the treatment period was 21 d，the clinical effect was assessed after two cycles.The efficacy and toxic side effect of two groups were compared.Results RR of the observation group was higher than that of control group，the difference was statistically significant（P＜0.05）.The incidence of leukopenia，thrombocytopenia，fever，gastrointestinal reactions and other relatively adverse reactions incidence in the observation group were lower than that of control group，the differences were statistically significant（P＜0.05）；while the incidence of anemia，peripheral neurotoxicity in the observation group were relatively little difference in the control group，there were no statistically significant difference between the two groups（P＞0.05）.Conclusion Gemcitabine plus program has a certain effect on relapsed or refractory non-Hodgkin's lymphoma，mild toxicity，and the patient can tolerate.

［Key words］Lymphoma；Relapsed or refractory；Gemcitabine；Oxaliplatin；Dexamethasone

淋巴瘤属于血液系统恶性疾病，多发生于淋巴结和淋巴组织，异质性、结外侵袭性等是淋巴瘤的主要特点［1］。淋巴瘤可分为霍奇金淋巴瘤（Hodgkin's lymphoma，HL）和非霍奇金淋巴瘤（non-Hodgkin lymphoma，NHL），其中非霍奇金淋巴瘤更为常见。虽然大部分的非霍奇金淋巴瘤患者对放疗或化疗都比较敏感，非霍奇金淋巴瘤患者中约有40%采用常规化疗后可完全缓解，但其他患者化疗效果并不明显或化疗缓解后很快复发，导致再次治疗缓解率很低［2］。……